Skip to the content

In line with Government`s vision to broaden the economic space, the Economic Development Board has identified medical (red) biotechnology as a sector of immense potential with high value-added activities.

Mauritius has a nascent clinical research industry which presents enormous potential for expansion. The introduction of the Clinical Trials Act in 2011, has led to significant emphasis on clinical research. The medical biotechnology sector accounts for a turnover in excess of MUR 2.3 billion and there are currently 4 Contract Research Organizations operating on the island and carrying out trials on various pathologies such as hepatitis, diabetes, HIV etc.

Mauritius represents a multi-ethnic, drug naive population. With infectious and lifestyle diseases like diabetes, cardiovascular diseases, cancer, hypertension prevailing in the countries and countries of the region, there is great opportunity for running clinical trials.


  • accelerated depreciation of 50% in respect of capital expenditure incurred on R&D, that is the investment cost is fully amortised in 2 years
  • a double deduction in respect of qualifying expenditure on R&D directly related to the entity’s trade or business and provided the R&D is carried out in Mauritius.

More than 1000 trials carried out on cosmetic and pharmaceutical products

No. of players: 25

Total employment: 1,275

Contact the Lifesciences Unit

The 'First name' field is required
The 'Last name' field is required
Please enter a valid Email address